

Lipid Mediators in Health and Disease

A Tribute to Bengt Samuelsson

PROGRAM

Venue: Nobel Forum, Nobels väg 1, Karolinska Institutet, August 27-29, 2014.

Wednesday, August 27

- | | |
|-------------|--|
| 11.30-13.00 | Lunch |
| 13.00-13.10 | Welcome address
<i>Jesper Z. Haeggström</i> |
| 13.10-14.00 | Key Note Lecture
<i>Bengt Samuelsson</i> |

Session 1: *Phospholipases A₂*

Chairpersons:

- | | |
|-------------|--|
| 14.00-14.30 | PLA ₂ , structures, mechanisms and membrane interactions
<i>Edward A. Dennis</i> |
| 14.30-15.00 | Roles of cPLA ₂ in disease
<i>Takao Shimizu</i> |
| 15.00-15.30 | Novel biological functions of PLA ₂
<i>Makoto Murakami</i> |
| 15.30-15.50 | <i>Coffee break</i> |

13.30-14.00	Receptors for leukotriene B ₄ <i>Takehiko Yokomizo</i>
14.00-14.30	Cysteinyl-leukotrienes, enzymes and novel receptors <i>K. Frank Austen</i>
14.30-15.00	Anti-leukotrienes in the clinical management of asthma <i>Sven-Erik Dahlén</i>
15.00-15.30	<i>Coffee break</i>
15.30-16.00	12R- lipoxygenase, a key role in human ischtyosis <i>Alan R. Brash</i>
16.30-17.00	Enzymes in the leukotriene cascade, novel therapeutic opportunities <i>Jesper Z. Haeggström</i>

Friday, August 29

Session 4: Novel mediators in resolution of inflammation

Chairpersons:

09.00-09.25	Omega-3 fatty acids and synthesis of proresolving mediators <i>Charles N. Serhan</i>
09.25-09.50	Proresolving lipid mediators in asthma <i>Bruce Levy</i>
09.50-10.15	Resolvins for treatment of dry eye <i>Per Gjorstrup</i>
10.15-10.40	Lipid signaling for vision and neuroprotection <i>Nicolas G. Bazan</i>
10.40-11.00	<i>Coffee break</i>

Session 5: Sphingolipids, from inborn neurodegenerative disorders to inflammation

Chairpersons:

- | | |
|-------------|--|
| 11.00-11.30 | Discovery and bioactions of sphingosine-1-phosphate
<i>Sarah Spiegel</i> |
| 11.30-12.00 | Sphingosine kinases
<i>Lina M. Obeid</i> |
| 12.00-13.00 | <i>Lunch</i> |
| 13.00-13.30 | Receptors for sphingosine-1-phosphate
<i>Timothy Hla</i> |
| 13.30-14.00 | Animal models for sphingolipid deficiency
<i>Richard L. Proia</i> |
| 14.00-14.30 | Fingolimod, a first line drug for treatment of MS
<i>Volker Brinkmann</i> |

Concluding remarks: Jesper Z. Haeggström, Tim Hla, Charles N. Serhan, Takao Shimizu